Cohort heterogeneity and AD biomarkers in older adults without significant cognitive impairment: A comparison of U.S. POINTER and ADNI

Background A key focus of the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is recruitment of unimpaired older individuals at risk for cognitive decline with heterogeneous characteristics (under‐represented racial and ethnicity groups (URG), family h...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alzheimer's & dementia 2023-12, Vol.19 (S16), p.n/a
Hauptverfasser: Landau, Susan M., Harrison, Theresa M., Ward, Tyler J., Baker, Suzanne L., Koeppe, Robert A., Vemuri, Prashanthi, Lockhart, Samuel N., Jung, Youngkyoo, Harvey, Danielle J., Lovato, Laura, Toga, Arthur W., Masdeu, Joseph C., Oh, Hwamee, Gitelman, Darren R., Aggarwal, Neelum T., Farias, Sarah Tomaszewski, Papp, Kathryn V., Snyder, Heather M, Baker, Laura D, Decarli, Charles, Jagust, William J.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background A key focus of the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is recruitment of unimpaired older individuals at risk for cognitive decline with heterogeneous characteristics (under‐represented racial and ethnicity groups (URG), family history of cognitive decline, hypertension, geographic diversity), and a subset of individuals undergo PET and MRI. Method To examine effects of heterogeneity on relationships between risk factors, AD biomarkers (Aβ and entorhinal tau PET, hippocampal volume (HV)) and cognition (global, executive function, and memory) were examined from U.S. POINTER neuroimaging participants (N = 602, about 65% of the anticipated total sample) and a subset of Alzheimer’s Disease Neuroimaging Initiative participants (N = 503). Neuroimaging data were processed and analyzed using harmonized methods across studies. Some cohort‐specific measurements were standardized using a within‐cohort reference group (Aβ‐negative individuals
ISSN:1552-5260
1552-5279
DOI:10.1002/alz.080245